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Background: Polycystic ovary syndrome is characterized by hyperandrogenism. In 
pregnancy, testosterone levels may be higher in women with PCOS compared to controls. 
Aims: To compare total testosterone (TT), free testosterone (FT), and sex hormone binding 
globulin (SHBG) levels in 3rd trimester pregnant women with PCOS and controls and to 
establish reference ranges for TT, FT, and SHBG in PCOS and controls.  
Methods: The study was part of the prospective study, Odense Child Cohort. PCOS was 
diagnosed by questionnaires and/or patient records. Fasting blood samples were collected at 
gestational week 28 and plasma TT was measured by liquid chromatography-tandem mass 
spectrometry in women with PCOS (n=145) and in women without PCOS (controls, 
n=1,341). 
Results: Levels of TT (mean: 2.4 vs. 2.0 nmol/L) and FT (mean: 0.005 vs. 0.004 nmol/L) 
were higher, whereas SHBG levels (mean: 447 vs. 477 nmol/L) were lower in women with 
PCOS vs. controls (all P<0.001). Reference intervals for TT, FT, and SHBG in women with 
PCOS and controls were overlapping and partitioning of reference intervals was an 
ambiguous decision. In multiple regression analyses, TT and FT levels were positively 
associated with PCOS status and BMI and inversely associated with age and parity. Offspring 
gender did not predict maternal TT and FT.  
Conclusions: TT and FT levels were higher in 3rd trimester pregnant women with PCOS 
compared to controls. Separate reference interval for FT in women with PCOS should be 
considered.   
We performed reference intervals for 3rd trimester total and free testosterone and SHBG in 145 
women with PCOS and 1,341 controls. We suggest separate reference interval for free testosterone.   
. 
Introduction 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-
aged women with prevalence around 10-15% (1). PCOS is usually diagnosed by the 2003 
ESHRE Rotterdam criteria (2) requiring two of the following: 1) clinical or biochemical 
evidence of androgen excess, 2) oligomenorrhea or amenorrhoea, and 3) polycystic ovaries. 
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Androgen excess is a key feature of PCOS and is present in around 70% of diagnosed women 
(1;2). More than 80% of women presenting with hirsutism have PCOS (3;4). Assessment of 
biochemical androgen excess in women includes measurement of total testosterone (TT), sex 
hormone-binding globulin (SHBG) and calculation of free testosterone (FT) or free androgen 
index (5). Precise measurement of TT requires use of high quality assays (5;6). BMI is 
inversely associated with SHBG and BMI is positively associated with higher FT (7), 
whereas TT and FT levels in women with PCOS decrease with age (8;9). 
During pregnancy, significant changes occur in maternal circulating concentrations of 
TT, FT, and SHBG (10;11). After 9th week of gestation, high levels of estrogen are produced 
by the placenta. Estrogen stimulates SHBG production, and SHBG levels remain 5 to 10-fold 
increased throughout pregnancy (10;12). During normal pregnancy, elevated estrogen and 
SHBG levels were positively associated with increased levels of TT (10-12). The balance 
between SHBG and TT resulted in circulating FT levels within the non-pregnant range until 
3rd trimester (11). However, FT levels increased significantly during 3rd trimester (11). In 
pregnant women with PCOS, circulating levels of TT and FT may be higher compared to 
controls (13;14). To our knowledge, only one study reported tandem mass spectrometry 
derived TT reference ranges in pregnant women (15). However, only TT data for 1st and 2nd 
trimester were presented and PCOS status of included women was not reported (15). We are 
not aware of previous papers on reference ranges for FT and SHBG in women with PCOS 
and controls. 
In the present study, we measured 3rd trimester maternal TT and SHBG levels and 
calculated FT in pregnant women with and without PCOS and calculated reference ranges for 
TT, FT, and SHBG. We hypothesized that women with PCOS could have higher levels of 
testosterone compared to controls in 3rd trimester, and we tested the hypothesis that separate 
reference intervals (partitioning) for TT, FT, and SHBG should be recommended in women 
with PCOS and controls.  
Population and method 
This study was part of Odense Child Cohort (OCC) (16). OCC is a joint research project 
where pregnant women within the Municipality of Odense, Denmark, were recruited between 
01/01/2010 and 31/12/2012. Out of 6,707 pregnancies, 4,017 women received information 
about the study cohort, and 2,874 pregnant women were included in OCC (Figure 1, 
flowchart). Women had to give additional consent to attend for fasting blood samples around 
gestation week 25. After excluding multiple pregnancies (n=56), fasting blood samples on 
androgen-status were available in 1,526 of 2,818 women. Seventeen women were pregnant 
more than once within the inclusion period (only first pregnancy included in dataset) and 
twenty women were excluded due to unknown PCOS status (Figure 1, flowchart). Three 
women in the control group were excluded because of high TT levels (14.6, 14.9 and 25.7 
nmol/L). No cause of high TT was found by review of the analytical method or patient 
records. The remaining 1,486 women were included in the study (145 PCOS and 1,341 
controls).  
PCOS status 
PCOS was defined according to the Rotterdam criteria (2). Data on PCOS diagnosis and 
hirsutism before pregnancy were collected from a detailed electronic questionnaire on the 
mothers’ health during 2nd trimester (17). Women were classified with PCOS if they replied 
yes to the question ‘has a doctor ever told you that you have PCOS?’ or they reported both 
facial hair and oligomenorrhea (menstrual cycles of ≥ 35 days). A unique ultrasound 
diagnosis of PCO (PCOM) did not qualify for a PCOS diagnosis. Women with self-reported 
facial hirsutism and regular menses were included (n = 61) in the PCOS cohort, as around 
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80% of women presenting with hirsutism have PCOS (4). Some of the women with self-
reported facial hirsutism could have idiopathic hirsutism (IH), and therefore we repeated 
calculations after excluding these women from the patient cohort (sensitivity analysis)(18). 
Data on PCOS status in questionnaire non-responders were extracted from medical records. 
Cohort staff was unaware of maternal PCOS diagnosis, and PCOS diagnosis did not affect 
follow up during pregnancy. The control population included women with regular menstrual 
cycle (<35 days) before conception and no signs of androgen excess (hirsutism and/or acne).  
Covariates 
Age, pre-pregnancy body mass index (BMI), parity, and smoking status were obtained from 
patient records using social security numbers.  
Gestational diabetes (GDM):  
Gestational diabetes mellitus (GDM) was defined as a 2-h capillary glucose ≥  9.0 mmol/L 
according to Danish guidelines for antenatal care (19). GDM diagnosed at gestation weeks 
14-20 was obtained by chart review. Women with risk factors for GDM were offered a 
diagnostic OGTT (75 g glucose) at gestational age 28–30 weeks. Risk factors for GDM 
included BMI ≥ 27 kg/m2, family history of diabetes mellitus, glucosuria during pregnancy, 
previous GDM or previous delivery of a macrocosmic child (19). For each woman 
undergoing an OGTT by indication, one random woman without GDM risk factors from 
OCC was offered an OGTT.   
Depression:  
Information of a hospital diagnosis of depression was obtained by ICD10 codes from the 
National Patient Register (NPR). The diagnosis of depression should occur within pregnancy 
to be included.    
Assays 
Morning, fasting maternal venous samples were taken around 27-28th week of gestation, 
centrifuged for 10 min. at 3,000 revolutions/min) and stored at -20 ºC degrees. Samples were 
analysed for TT using liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Plasma samples were extracted by supported liquid extraction and the eluate was evaporated 
and reconstituted before analysis. The LC-MS/MS analysis was calibrated by in-house 
prepared calibrators and the relative standard deviation (SD) was <10 %. Quality was assured 
by monthly participation in the external quality control program for steroid hormones from 
The United Kingdom National External Quality Assessment Service (NEQAS, UK). SHBG 
was determined on serum samples by a Roche assay on Cobas e602 (Indianapolis, US) with a 
precision of 1.8 – 4.0 % (14.9-21.9 nmol/L). FT levels were calculated using the Vermeulen 
equation (20) assuming a plasma albumin concentration of 42 g/L. Albumin concentrations 
are generally lower during pregnancy (21), and calculations of FT were repeated with 
assumption of plasma albumin 32.5 g/L.  
Ethical approval 
The study was performed in accordance with the Helsinki Declaration II and approved by the 
Regional Ethical Review Committee (Project ID S-20090130) and the Danish Data 
Protection Agency (j.no. 18/15692) (16). All participants received written and oral 
information and provided their written consent for participation (16).  
Statistical analysis 
Baseline characteristics were reported as mean (±SD) or percentages (n). The normality of 
data was evaluated using histograms and Skewness/Kurtosis test. TT and FT data were 
normalized by natural logarithm (ln) transformation, whereas SHBG data were normally 
distributed. Reference intervals for TT and FT were established using the anti-ln of mean ± 
1.96 SD on ln-transformed data. 
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For each reference interval (TT, FT, and SHBG), potential partitioning according to 
PCOS status (PCOS and controls) was assessed using the method proposed by Lahti et al. 
(22). Partitioning was used to determine if separate reference intervals should be 
recommended in women with PCOS regarding TT, FT, and SHBG (partitioning 
recommended) or women with PCOS were part of the reference intervals for controls 
(partitioning not recommended). If the decision to partition was not clear (ambiguous), we 
discussed if non-partitioning could lead to over-diagnosis of elevated testosterone levels 
during pregnancy. When data were normalized, the ratio between SD in women with PCOS 
and controls was determined (larger SD divided by smaller SD). If this ratio, R, was >1.5, 
partitioning was recommended. If R was ≤1.5, then the difference between upper (DU) and 
lower (DL) reference limits in women with PCOS and controls (∆) was calculated, and the 
SD of the narrower subgroup (PCOS or controls) was used as a scale unit (∆/SD). If ∆/SD 
was ≥0.75 for either upper or lower reference limits or both, partitioning was recommended, 
if ∆/SD was 0.25-0.75 for either upper or lower reference limits or both and neither was 
≥0.75, partitioning was an ambiguous decision, and if ∆/SD was <0.25 for both upper and 
lower reference limits, partitioning was not relevant.  
The fraction of women with PCOS and controls with TT, FT, and SHBG results above 
the upper limit in controls was calculated. Finally, linear regression models were performed 
with ln-transformed values of TT and FT as the dependant variable and PCOS/control status 
as the independent variable and age, BMI, parity, offspring gender, and smoking as 
covariates. The assumptions underlying multiple linear regression modelling were checked 
and accepted. Normality and homoscedasticity of residuals in models were inspected 
graphically, and multicollinearity was checked formally.  
Levels of TT, FT, and SHBG could be affected by a diagnosis of GDM, applied criteria 
for PCOS, and a diagnosis of depression. Therefore, we performed three sensitivity analyses, 
where we omitted the following individuals (PCOS and controls): 1: women diagnosed with 
GDM, 2: women with hirsutism and no information of menstrual cycles and ultrasound 
(possible idiopathic hirsutism), and 3: women with a diagnosis of depression during 
pregnancy until testosterone assessment.   
All data were analysed using STATA/IC (version 15.1, StataCorp LP). A P-value <0.05 
was considered significant. 
Results 
Baseline characteristics of pregnant women with PCOS+IH vs. controls are shown in Table 1. 
Women with PCOS+IH and controls were comparable regarding BMI, age, parity, offspring 
gender, and smoking status. More women with PCOS+IH had received fertility treatment 
compared to controls. TT and FT levels were higher in PCOS+IH vs. controls, whereas 
SHBG levels were lower. Differences in TT, FT, and SHBG between PCOS+IH and controls 
remained significant when women were divided according to offspring gender (Table 1). TT, 
FT, and SHBG levels were comparable in women pregnant with male and female offspring 
within PCOS and within controls (Table 2) 
Table 3 shows mean (SD) and 95% reference intervals for TT, FT and SHBG in women 
with PCOS+IH and controls.  
Table 4 shows the partitioning of reference intervals for TT, FT, and SHBG according to 
PCOS status. Partitioning of TT, FT, and SHBG reference intervals for PCOS+IH and 
controls was an ambiguous decision.  
The percentage of women with PCOS+IH and controls with TT, FT, and SHBG above 
the upper cut off limit for controls is shown in Table 5. A higher percentage of women with 
PCOS+IH than controls had FT levels above the cut off limit (7.6 vs. 3.6%, p= 0.02).  
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Linear regression analyses (Table 6 and 7) showed that PCOS status predicted TT 
(P<0.001) and FT (P<0.001) and this remained significant after adjusting for maternal age, 
BMI, parity, offspring gender, and smoking.  
We repeated calculations of FT assuming a lower albumin concentration of 32.5 g/L 
instead of 42 g/L.  Changing the concentration of albumin resulted in very small changes in 
calculated FT levels (4-5th decimal)(18). Significant results of the study were not affected by 
changing the assumed concentration of albumin (data not presented).   
Sensitivity analyses  
GDM:  
Thirty six women had a diagnosis of GDM (PCOS n= 2 and controls n=34). Omitting women 
with a diagnosis of GDM did not change significant results except that partitioning of the 
lower limit of the reference interval for SHBG was changed from “not recommended” to 
“ambiguous”, data not presented.   
PCOS diagnosis (18):  
Sixty-one women had a possible diagnosis of IH. Women with possible IH resembled the 
remaining women in the PCOS cohort (n=84) regarding age, BMI, parity, offspring gender 
and smoking, whereas less women with IH compared to the remaining women with PCOS 
had undergone fertility treatment. FT and TT levels were lower in women with possible IH 
compared to the rest of the women in the PCOS group, whereas SHBG levels were 
comparable. The 95% reference interval for TT was 1.03-6.50 nmol/L and FT 0.002-0.017 
nmol/L in women with PCOS (n=84).  
Partitioning was repeated after excluding women with possible IH from the PCOS group. 
This did not change significant results except that partitioning of the lower limit of the 
reference interval for TT was changed from “ambiguous” to “recommended”.   
Depression:  
Seven women had a hospital diagnosis of depression during pregnancy (PCOS: 3/145=2.1% 
vs. controls: 4/1,341= 0.3%, p=0.003). Removing women with depression from the study 
population did not change significant findings of the study (data not shown).    
Discussion 
In the present study, we performed reference intervals for 3rd trimester levels of TT and FT in 
a well described cohort of women divided according to PCOS status. We found that maternal 
concentrations of TT and FT were higher and SHBG were lower in pregnant women with 
PCOS compared to controls. Reference intervals in women with PCOS and controls were 
overlapping, and performing separate reference intervals for the two study populations was 
an ambiguous decision (22). TT and FT levels were positively affected by PCOS status and 
BMI and inversely affected by maternal age and parity, whereas offspring gender and 
smoking did not affect TT and FT levels.   
The present data expand the previous study by Neale et al. (15), who reported tandem MS 
derived reference range for TT in 60 pregnant women during the 1st (reference range TT: 
0.6–4.9 nmol/L) and 2nd trimester (reference range TT: 0.9–4.9 nmol/L). In comparison, the 
reference range for TT in non-pregnant women determined by Neale (15) and our local 
laboratory was comparable at < 1.7 nmol/L. Therefore, our findings of a 3rd trimester 
reference interval for TT at 0.7–5.3 nmol/L in controls could support a hypothesis that TT 
levels are elevated from 1st trimester and could increase further during the last trimester. This 
was supported by a recent prospective study by Schock et al. in 71 pregnant women with 
unreported PCOS status, where TT levels showed a weak and gradual increase throughout 
pregnancy (12). Several mechanisms were suggested to influence TT levels in pregnancy. 
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Levels of SHBG increased, but became stable in the last trimester (10) and could not explain 
increased TT during 3rd trimester. Instead, estradiol levels increase substantially throughout 
the whole pregnancy (10;12). Furthermore, Bamman et al. measured FT by equilibrium 
dialysis and found stable FT levels before week 28 followed by a significant increase from a 
mean value of 0.040 to 0.106 nmol/L after week 28 (11). The authors suggested that 
increasing levels of FT during the last trimester could be due to increased testosterone 
production by the foetus (11). The origin of possible foetal testosterone production is 
undetermined. TT levels in the amniotic fluid of male foetuses were significantly higher than 
TT levels of female foetuses, but the present study and a previous study (11) found 
comparable maternal TT levels irrespective of foetal sex. The present and previous studies 
(13;23-25) supported that PCOS status affected levels of TT and FT levels. Furthermore, our 
results supported that the effect of PCOS on TT and FT levels remained significant after 
correction for age, BMI, parity and smoking. Several previous studies in pregnant women 
with PCOS applied immunoassays to establish TT levels (23-25). Direct immunoassays are 
not considered gold standard in women (5;6). In a recent study, Caanen et al. evaluated TT 
levels by LC-MS/MS around 20 weeks of gestation and by delivery in mothers with PCOS 
(n=20) vs. controls (n=83) (13) and found significantly higher TT levels in PCOS vs. controls 
at both times of gestation and also in umbilical cord blood of mothers with PCOS (13). FT 
and SHBG levels were not presented in the article (13) and the mechanism for higher TT 
levels in PCOS vs. controls still needs to be determined. However, higher testosterone levels 
in pregnant women with PCOS compared to controls could question the complete 
suppression of ovarian and adrenal activity during pregnancy in PCOS (13;26). This 
hypothesis was supported by the inverse association between age and testosterone levels both 
outside and during pregnancy (9;26). Unfortunately, we did not have access to adrenal 
hormones such as dehydroepiandrostenedione sulphate (DHEAS) in the present study. Our 
finding of a positive association between BMI and TT could be due to increased conversion 
of androgens in the adipose tissue (26). Several polymorphisms in the aromatase enzyme in 
the placenta could also be a predictor of maternal TT levels (26). Furthermore, previous 
studies supported that TT levels in pregnancy may also be stimulated by depression (26), 
weight gain (26;27), and smoking (12), which could all be more prevalent in women with 
PCOS compared to controls (28;29).  
In the present study we tested the hypothesis that partitioning of reference intervals for 
TT, FT, and SHBG in women with PCOS and controls would be recommended due to higher 
levels of testosterone in PCOS. We found that reference intervals for TT, FT, and SHBG in 
women with PCOS and controls were overlapping, and performing separate reference 
intervals for the two study populations was an ambiguous decision (22). We found that twice 
as many women with PCOS compared to controls had FT levels above the reference interval 
for controls. Our study therefore supports that partitioning of reference intervals for FT 
should be considered. The importance of measuring testosterone levels during pregnancy 
remains to be established. Measurement of pre-pregnant (i.e. low) levels of TT and SHBG in 
pregnancy could be due to insufficient production of estrogen during pregnancy and have 
been associated with high risk of abortion (11). Naver et al. reported that increased risk of 
preterm delivery and pre-eclampsia was confined to hyperandrogenic women with PCOS, 
indicating that hyperandrogenism might influence the risk of pregnancy complications (30). 
Furthermore, the impact of higher cord blood testosterone levels in children born of mothers 
with PCOS needs to be determined in future studies (26).    
Strengths and limitations may apply to the present study. The study included 145 women 
with PCOS and we used high quality assays to measure TT. In the present study design, 
women with PCOS were not followed more closely than controls, i.e. there was no 
surveillance bias. We consider this a study strength, as the metabolic risk in lean women with 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2018-00889/5060464
by Danish Regions user
on 01 August 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00889 
 
 
7
PCOS is still debated (31). The diagnosis of PCOS was based on a combination of self-
reported PCOS and PCOS diagnosis from medical records, as PCOS cannot be diagnosed 
during pregnancy. Adding self-reported PCOS allowed us to identify cases without a hospital 
diagnosis, these women were diagnosed and treated by a general practitioner or private 
gynecologist. This resulted in a PCOS cohort of relatively lean and healthy women, but 
would arguably be more applicable to PCOS in the general population. However, some 
women in the control population could have undiagnosed PCOS and women with IH could 
be misclassified as PCOS, which in both situations would increase the risk of type 2 error. 
We performed a sensitivity analysis where we excluded women with possible IH and this did 
not change significant results. Therefore we chose to keep women with possible IH as part of 
the PCOS cohort.  Results for FT were derived from TT and SHBG, as we used Vermeulen’s 
equation with estimated levels of albumin. We chose this method, as it resembles generally 
applied procedures in the daily clinic, where direct measurement of FT by microdialysis is 
not available and albumin is not measured routinely (32). Albumin levels decrease during 
pregnancy and the level is 25% decreased during 3rd trimester (21). Therefore, we repeated 
FT calculations with an assumption of lover albumin levels. This did not change significant 
results. In the clinic it is not general practice to adjust estimated albumin concentration 
according to pregnancy status so we kept an assumed plasma albumin concentration of 4.3 
g/dL (20). Furthermore, we expect that a diagnosis of PCOS would not affect the tendency to 
decreased albumin levels during pregnancy. The correct method for estimation of FT is 
highly debated (32;33), and the present study underlines the importance of general consensus 
also during pregnancy.   
The women participating in OCC were more ethnically homogenous, leaner, more 
educated and were less likely to smoke compared to the background population (16). This is 
often a problem in cohort studies, where minorities and people of lower social status tend to 
drop out. The presented reference intervals for TT, FT, and SHBG therefore need to be 
reproduced in a more obese study population and in women of other ethnicities.     
Conclusions 
Maternal levels of total and free testosterone were higher and SHBG levels were lower in 3rd 
trimester women with PCOS compared to controls. Specific reference ranges for TT, FT, and 
SHBG in women with PCOS was an ambiguous decision, but should be considered for FT.  
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Figure 1 Flowchart of study population in Odense Child Cohort (OCC) 
Table 1 Baseline characteristics in women with PCOS and controls  
Table 1 Baseline characteristics in women with PCOS+IH and controls  
 
All (n=1,486) PCOS+IH (n=145) Controls (n=1,341) PCOS+IH vs. 
controls P value 
BMI (kg/m2)§ 24.1  (20.3; 28.7) 24.6 ( 20.2; 29.9) 24.1 (20.3; 28.5) 0.18 
Age (years) 30 (±5) 31 (±5) 30 (±5) 0.21 
Parity     
  0 58% (857) 55% (80) 58% (777) 0.81 
  1 32% (477) 34% (49) 32% (428)  
  >1 10% (152) 11% (16) 10% (136)  
Offspring gender     
Female 47% (699) 45% (65) 47% (634) 0.57 
Male 53% (787) 55% (80) 53% (707)  
Hirsutism (n=1,081) (n=127) (n=954)  
  Yes 9% (92) 72% (92) 0% (0) <0.001 
  No 91% (989) 28% (35) 100% (954)  
Fertility treatment (n=1,032) (n=113) (n=919)  
  Yes 14% (140) 35% (40) 11% (100) <0.001 
  No 86% (892) 65% (73) 89% (819)  
Smoking (n=1,484) (n=145) (n=1,339)  
  Yes 4% (59) 5% (7) 4% (52) 0.66 
  No 96% (1,425) 95% (138) 96% (1,287)  
T testosterone (nmol/L)§ (n=1,486) (n=145) (n=1341)  
2.0 (1.2; 3.3) 2.4 (1.4; 3.9) 2.0 (1.2; 3.3) <0.001 
F testosterone (nmol/L)§ (n=1,478) (n=144) (n=1,334)  
0.004 (0.002; 0.007) 0.005 (0.003; 0.009) 0.004 (0.002; 0.007) <0.001 
SHBG (nmol/L) (n=1,478) (n= 144) (n= 1,334)  
474 (±112) 447 (±110) 477 (±112) 0.003 
Pregnancy with female offspring    
T testosterone (nmol/L)§ (n=699) (n=65) (n=634)  
2.0 (1.2; 3.3) 2.5 (1.5; 4.0) 2.0 (1.2; 3.3) <0.001 
F testosterone (nmol/L)§ (n=694) (n=64) (n=630)  
0.004 (0.002; 0.007) 0.005 (0.003; 0.009) 0.004 (0.002; 0.007) <0.001 
SHBG (nmol/L) (n=694) (n=64) (n=630)  
479 (±112) 444 (±116) 482 (±112) 0.005 
Pregnancy with male offspring    
T testosterone (nmol/L)§ (n=787) (n=80) (n=707)  
2.0 (1.2; 3.3) 2.3 (1.3; 3.8) 2.0 (1.2; 3.3) 0.03 
F testosterone (nmol/L)§ (n=784) (n=80) (n=704)  
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2018-00889/5060464
by Danish Regions user
on 01 August 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00889 
 
 
11 
0.004 (0.002; 0.007) 0.005 (0.003; 0.008) 0.004 (0.002; 0.007) 0.005 
SHBG (nmol/L) (n=784) (n=80) (n=704)  
470 (±111) 450 (±107) 472 (±112) 0.13 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin. 
Data presented as percent of group (number) 
Age and SHBG were Gaussian distributed and presented as arithmetic mean (±SD) 
§
 BMI, T testosterone and F testosterone were ln-transformed, geometric mean (mean – SD; mean + SD). 
P-value for differences between PCOS status tested using t-test for continuous variables and Chi squared test for 
categorical variables. 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin. 
Data presented as percent of group (number) 
Age and SHBG were Gaussian distributed and presented as arithmetic mean (±SD) 
§
 BMI, T testosterone and F testosterone were ln-transformed, geometric mean (mean – SD; mean + SD). 
P-value for differences between PCOS status tested using t-test for continuous variables and Chi squared test for 
categorical variables. 
Table 2 Maternal testosterone concentrations according to offspring gender and PCOS status 
Table 2 Maternal testosterone concentrations according to offspring gender and PCOS status 
 PCOS+IH Controls 
 Pregnancy with 
female offspring 
Pregnancy with male 
offspring 
P-value Pregnancy with 
female offspring 
Pregnancy with male 
offspring 
P-value 
T testosterone 
(nmol/L)§ 
(n=65) (n=80)  (n=634) (n=707)  
2.5 (1.5; 4.0) 2.3 (1.3; 3.8) 0.23 2.0 (1.2; 3.3) 2.0 (1.2; 3.3) 0.94 
F testosterone 
(nmol/L)§ 
(n=64) (n=80)  (n=630) (n=704)  
0.005 (0.003; 0.009) 0.005 (0.003; 0.008) 0.21 0.004 (0.002; 0.007) 0.004 (0.002; 0.007) 0.37 
SHBG 
(nmol/L) 
(n=64) (n=80)  (n=630) (n=704)  
444 (±116) 450 (±107) 0.73 482 (±112) 472 (±112) 0.10 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin 
§T testosterone and F testosterone were ln-transformed and presented as geometric mean (mean – SD; mean + 
SD) 
SHBG was Gaussian distributed and presented as arithmetic mean (±SD) 
P-value for differences between PCOS status tested using t-test for continuous variables 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin 
§T testosterone and F testosterone were ln-transformed and presented as geometric mean (mean – SD; mean + 
SD) 
SHBG was Gaussian distributed and presented as arithmetic mean (±SD) 
P-value for differences between PCOS status tested using t-test for continuous variables 
Table 3 Total testosterone, free testosterone and SHBG in women with PCOS and controls 
Table 3 Total testosterone, free testosterone and SHBG in women with PCOS+IH and 
controls 
 Mean (SD)§ 95% Reference Interval 
PCOS+IH   
T testosterone (n=145)§ 2.35 (1.43; 3.89) 0.88–6.30  
F testosterone (n=144)§ 0.005 (0.003; 0.009)  0.002–0.015 
SHBG (n=144) 447 (±110) 231–664 
Controls   
T testosterone (n=1,341)§ 1.97  (1.18; 3.27) 0.73–5.32 
F testosterone (n=1,334)§ 0.004 (0.002; 0.007) 0.001–0.011 
SHBG (n=1,334) 477 (±112) 258–696 
All   
T testosterone (n=1,486)§ 2.00 (1.21; 3.33) 0.74–5.44 
F testosterone (n=1,478)§ 0.004 (0.002; 0.007) 0.001–0.012 
SHBG (n=1,478) 474 (±112) 255–693 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin 
Unit for total testosterone, SHBG and free testosterone nmol/L 
§T testosterone and F testosterone were ln-transformed and presented as geometric mean (mean – SD; mean + 
SD) 
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SHBG was Gaussian distributed and presented as arithmetic mean (±SD) 
T testosterone: total testosterone, F testosterone: free testosterone, SHBG: Sex hormone binding globulin 
Unit for total testosterone, SHBG and free testosterone nmol/L 
§T testosterone and F testosterone were ln-transformed and presented as geometric mean (mean – SD; mean + 
SD) 
SHBG was Gaussian distributed and presented as arithmetic mean (±SD) 
Table 4 Partitioning of reference intervals for total and free testosterone and SHBG according 
to PCOS-status 
Table 4 Partitioning of reference intervals for total and free testosterone and SHBG according 
to PCOS-status 
 Data for group distribution  Partitioning criteria 
Conc, nmol/L ln(Conc)  
PCOS+IH  Controls PCOS+IH  Controls R DU DL ∆/SD Partitioning  for 
one end 
Conclusion on 
partitioning 
T 
testosterone 
(n=145) (n=1,341) (n=145) (n=1,341)       
Upper limit 6.30 5.32 1.841 1.671  0.17  0.34 Ambiguous Ambiguous 
Lower limit 0.88 0.73 -0.128 -0.315   0.19 0.38 Ambiguous 
Mean   0.856 0.678       
SD   0.502 0.507 1.01      
F 
testosterone 
(n=144) (n=1,334) (n=144) (n=1,334)       
Upper limit 0.015 0.011 -4.229 -4.474  0.25  0.47 Ambiguous Ambiguous 
Lower limit 0.002 0.001 -6.303 -6.539   0.24 0.45 Ambiguous 
Mean   -5.266 -5.507       
SD   0.529 0.527 1.00      
SHBG§ (n=144) (n=1,334)         
Upper limit 664 696 - -  32  0.29 Ambiguous Ambiguous 
Lower limit 231 258 - -   27 0.24 Not relevant 
Mean 447 477 - -       
SD 110 112 - - 1.01      
Data presented as 97.5% (upper limit) and 2.5% (lower limit)  
§ SHBG was Gaussian distributed and data were not ln-transformed 
R: Ratio of SD in women with PCOS and controls (larger SD divided by smaller SD) 
DU= Difference between upper limit in PCOS and controls (ln values for T testosterone and F testosterone) 
DL =Difference between lower limit in PCOS and controls (ln values for T testosterone and F testosterone) 
∆/SD  for upper limit: DU /SD of the narrower subgroup distribution 
∆/SD for lower limit: DL /SD of the narrower subgroup distribution  
Recommendations according to Lahti et al. 2002: ∆/SD ≥0.75: Partitioning recommended; ∆/SD 0.25–0.75, 
Ambiguous decision, ∆/SD <0.25: Partitioning not relevant 
Data presented as 97.5% (upper limit) and 2.5% (lower limit)  
§ SHBG was Gaussian distributed and data were not ln-transformed 
R: Ratio of SD in women with PCOS and controls (larger SD divided by smaller SD) 
DU= Difference between upper limit in PCOS and controls (ln values for T testosterone and F testosterone) 
DL =Difference between lower limit in PCOS and controls (ln values for T testosterone and F testosterone) 
∆/SD for upper limit: DU /SD of the narrower subgroup distribution 
∆/SD for lower limit: DL /SD of the narrower subgroup distribution  
Recommendations according to Lahti et al. 2002: ∆/SD ≥0.75: Partitioning recommended; ∆/SD 0.25–0.75, 
Ambiguous decision, ∆/SD <0.25: Partitioning not relevant 
Table 5 Fractions of women with PCOS and controls with testosterone and SHBG levels 
above the upper cut off limit for controls 
Table 5 Fractions of women with PCOS+IH and controls with testosterone and SHBG levels 
above the upper cut off limit for controls 
 
Cut off limit (nmol/L) PCOS+IH % (n) Controls % (n) P-value 
Total testosterone   ≥5.32  4.1 % (6/145) 3.2 % (43/1,341) 0.55 
Free testosterone  ≥0.011 7.6 % (11/144) 3.6 % (48/1,334) 0.02 
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13 
SHBG  ≥696 0.7 % (1/144) 2.6 % (34/1,334) 0.16 
Cut off limit for controls 
P-value represents Chi squared test, PCOS vs. controls 
Cut off limit for controls 
P-value represents Chi squared test, PCOS vs. controls 
Table 6 Regression models for total testosterone during pregnancy (n=1,486) 
Table 6 Regression models for total testosterone during pregnancy (n=1,486) 
 Model 1 (Crude) 
(n=1,486) 
Model 2 (n=1,486) Model 3 (n=1,486) Model 4 (n=1,486) Model 5 (n=1,484) 
PCOS 0.18  0.20  0.19  0.19  0.19  
(0.09; 0.27)  (0.12; 0.28)  (0.11; 0.28) (0.11; 0.28) (0.11; 0.27) 
(P<0.001) (P<0.001) (P<0.001) (P<0.001) (P<0.001) 
Age X -0.04   -0.03  -0.03  -0.03  
(-0.04; -0.03) (-0.04; -0.03) (-0.04; -0.03) (-0.04; -0.02) 
(P<0.001) (P<0.001) (P<0.001) (P<0.001) 
BMI X 0.001   0.002  0.002  0.002  
(-0.004; 0.007) (-0.003; 0.007) (-0.003; 0.007) (-0.003; 0.007) 
(P=0.58) (P=0.47) (P=0.47) (P=0.50) 
Parity X X -0.12  -0.12  -0.12  
(-0.15; -0.08) (-0.15; -0.08) (-0.15; -0.08) 
(P<0.001) (P<0.001) (P<0.001) 
Offspring 
gender 
(female) 
X X X 0.002  0.004  
(-0.05; 0.05) (-0.04; 0.05) 
(P=0.94) (P=0.87) 
Smoking X X X X 0.06  
(-0.06; 0.19) 
(P=0.33) 
R2 0.01 (P<0.001) 0.13 (P<0.001) 0.15(P<0.001) 0.15 (P<0.00) 0.15 (P<0.00) 
Data represent β-coefficients (95% CI) and adjusted R2 values 
Total testosterone was ln-transformed  
Models adjusted for PCOS status (control, PCOS), age, BMI, parity, offspring gender and smoking  
Data represent β-coefficients (95% CI) and adjusted R2 values 
Total testosterone was ln-transformed  
Models adjusted for PCOS status (control, PCOS), age, BMI, parity, offspring gender and smoking  
Table 7 Regression models for free testosterone during pregnancy (n=1,478) 
Table 7 Regression models for free testosterone during pregnancy (n=1,478) 
 Model 1 
(Crude) 
(n=1,478) 
Model 2 (n=1,478) Model 3 (n=1,478) Model 
4(n=1,478) 
Model 5 
(n=1,476) 
PCOS 0.24  0.25  0.25  0.25  0.24  
(0.15; 0.33) (0.16; 0.33) (0.16; 0.33) (0.16; 0.33) (0.16; 0.33) 
(P<0.001) (P<0.001) (P<0.001) (P<0.001) (P<0.001) 
Age X -0.04  -0.03  -0.03  -0.03  
(-0.04; -0.03) (-0.04; -0.02) (-0.04; -0.02) (-0.04; -0.02) 
(P<0.001) (P<0.001) (P<0.001) (P<0.001) 
BMI X 0.02 0.02  0.02  0.02  
(0.01; 0.02) (0.01; 0.02) (0.01; 0.02) (0.01; 0.02) 
(P<0.001) (P<0.001) (P<0.001) (P<0.001) 
Parity X X -0.10  -0.10  -0.10  
(-0.14; -0.06) (-0.14; -0.06) (-0.14; -0.06) 
(P<0.001) (P<0.001) (P<0.001) 
Offspring 
gender 
(female) 
X X X -0.01 -0.01 
(-0.06; 0.04) (-0.06; 0.04) 
(P=0.58) (P=0.58) 
Smoking X X X X 0.12 
(-0.001; 0.26) 
(P=0.05) 
R2 0.02 (P<0.001) 0.13 (P<0.001) 0.15 (P<0.001) 0.15 (P<0.001) 0.15 (P<0.001) 
Data represent β-coefficients (95% CI) and adjusted R2 values 
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Free testosterone was ln-transformed 
Models adjusted for PCOS status (control, PCOS), age, BMI, parity, offspring gender and smoking  
Data represent β-coefficients (95% CI) and adjusted R2 values 
Free testosterone was ln-transformed 
Models adjusted for PCOS status (control, PCOS), age, BMI, parity, offspring gender and smoking  
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